CompletedNot Applicable

An Exploratory Study of Chenghuang Circadian Rhythm Regulator in Subjects With Sleep Disorders

China15 participantsStarted 2025-06-06

Plain-language summary

This is a single arm, open-label, self-controlled clinical study to evaluate the sleep and immunity improvement of Chenghuang Circadian Rhythm Regulator in adult subjects with sleep disorders.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Difficult in sleep onset: sleep actigraphy device report sleep latency ≥ 30 mins;
✓. Or difficult in sleep maintenance: nighttime awakenings ≥2 times; or early morning awakenings; or total sleep duration \< 6 hours; or abnormal deep reported by actigraphy device;

What they're measuring

The global score of Pittsburgh Sleep Quality Index (PSQI)

Timeframe: Baseline, Day 7, 14, 21, 28

Trial details

NCT IDNCT07414381

SponsorShanghai Cell Therapy Group Co.,Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-07-18

View on ClinicalTrials.gov More Sleep Disorders trials